KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals (KALV) Stock Price & Analysis


KALV Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.12 - $17.06
Previous Close$10.08
Average Volume (3M)246.07K
Market Cap
Enterprise Value$181.22M
Total Cash (Recent Filing)$171.69M
Total Debt (Recent Filing)$8.48M
Price to Earnings (P/E)-2.8
Jul 06, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding34,169,438
10 Day Avg. Volume224,842
30 Day Avg. Volume246,070
Standard Deviation0.28
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.81
Price Target Upside91.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $4.12 and its highest was $17.06 in the past 12 months.
    What is KalVista Pharmaceuticals’s market cap?
    Currently, no data Available
    When is KalVista Pharmaceuticals’s upcoming earnings report date?
    KalVista Pharmaceuticals’s upcoming earnings report date is Jul 06, 2023 which is in 33 days.
      How were KalVista Pharmaceuticals’s earnings last quarter?
      KalVista Pharmaceuticals released its earnings results on Mar 09, 2023. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.985 by $0.235.
        Is KalVista Pharmaceuticals overvalued?
        According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does KalVista Pharmaceuticals pay dividends?
          KalVista Pharmaceuticals does not currently pay dividends.
          What is KalVista Pharmaceuticals’s EPS estimate?
          KalVista Pharmaceuticals’s EPS estimate is -$0.87.
            How many shares outstanding does KalVista Pharmaceuticals have?
            KalVista Pharmaceuticals has 34,169,437 shares outstanding.
              What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
              KalVista Pharmaceuticals reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.985. Following the earnings report the stock price went down -5.405%.
                Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
                Among the largest hedge funds holding KalVista Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds KalVista Pharmaceuticals’s shares valued at 8M.


                  KalVista Pharmaceuticals Stock Smart Score

                  The KalVista Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  KalVista Pharmaceuticals

                  KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.


                  Top 5 ETFs holding KALV

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  iShares Russell 3000 ETF
                  Vanguard Russell 3000 ETF
                  Dimensional U.S. Equity ETF
                  iShares Core S&P Total U.S. Stock Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold KALV. The ETFs are listed according to market value of KALV within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Eloxx Pharmaceuticals
                  Ultragenyx Pharmaceutical
                  Aclaris Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis